NCT07300280

A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)

A Clinical Study to Evaluate the Relative Bioavailability of FDC Tablets Containing Enlicitide and Rosuvastatin, Compared to Enlicitide and Rosuvastatin Administered Concomitantly as Single Entities, in Healthy Adult Participants

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This goal of this trial is to learn about two medicines, enlicitide and rosuvastatin, in healthy people. Researchers will compare the amounts of enlicitide and rosuvastatin in a person's body over time, when they are given as separate medicines and when they are combined into one tablet.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	MK-0616A	Enlicitide/rosuvastatin fixed dose combination (FDC) or enlicitide/rosuvastatin FDC formulation B oral tablets
DRUG	Enlicitide	Oral tablet
DRUG	Rosuvastatin	Oral tablet

Timeline

• Start date: 2025-12-29
• Primary completion: 2026-07-15
• Completion: 2026-07-22
• First posted: 2025-12-23
• Last updated: 2026-03-18

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study